Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
Select Page

Desentum raised 12 million euros for advancing allergy vaccine development

by raikeeoy | Feb 8, 2024 | News

Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being tested in a clinical study in Canada, raised 12 M€ in a funding round arranged by an investment service company Springvest Oyj. Desentum intends to...

Viimeisimmät artikkelit

  • Ilmoitus osakkeiden siirtymisestä Desentum Oy:n osakkeenomistajalle
  • Pekka Mattila conferred as Honorary Doctor at the University of Eastern Finland
  • Kutsu Desentum Oy:n varsinaiseen yhtiökokoukseen / Summons to Annual General Meeting of Desentum Oy
  • Desentum raised 12 million euros for advancing allergy vaccine development
  • Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy